Summary
The FDA approved a second generic version of the abortion pill mifepristone made by Evita Solutions. This approval followed a lengthy review process and sparked reactions from both supporters and opponents of abortion rights. Despite the approval, access to the drug remains restricted in many states due to legal challenges and state bans.
Key Facts
- The FDA approved a second generic version of mifepristone, a pill used to end pregnancies up to 10 weeks.
- The approval process for Evita's version took four years.
- Mifepristone was first approved in 2000 and made more accessible over time, including through mail-order delivery.
- The generic approvals allow multiple companies to sell cheaper versions after a drug's patent expires.
- Mifepristone is often used with another drug called misoprostol, accounting for around two-thirds of U.S. abortions.
- Some states have enacted bans or restrictions on the use of mifepristone, leading to ongoing legal challenges.
- Anti-abortion groups and some Republican lawmakers criticized the FDA's decision.
- Major medical associations argue against restrictions on mifepristone, citing a lack of scientific support.
